What's driving the Betaxolol Market Growth? Novartis AG, Genix Pharma (Pvt.) Ltd., East West Pharma, Hetero Healthcare Ltd. (GenX), Cadila Pharmaceuticals Ltd., Jawa Pharmaceuticals (INDIA) Pvt. Ltd., DAL Medical Services Company Ltd, Sentiss Pharma Pvt.

Increasing prevalence of glaucoma worldwide is propelling growth of the market. According to the Glaucoma research Foundation, glaucoma is the leading cause of irreversible blindness worldwide. Around 10% of the glaucoma patients who receive proper treatment still experience a loss of vision. Around 64.3 million people were estimated to be suffering from glaucoma worldwide, in 2013. Furthermore, according to the American Academy of Ophthalmology, the prevalence of glaucoma is high in Africa and Latin America. Patients who fail to respond to medications, undergo trabeculectomy surgery.

However, few patients do not get complete relief from glaucoma even after trabeculectomy surgery. Therefore, novel treatment options are required for providing relief to such patients. Reducing intra-ocular pressure is the most important long term medical need of refractory glaucoma patients, which can be overcome by the use of Betaxolol drug, this in turn is expected to create lucrative opportunities for market growth.

Moreover, people suffering from diabetic retinopathy are more prone to glaucoma. The condition is associated with abnormal blood vessel growth, which can result in retinopathy and leads to blockage of natural drainage of the eye. Thus, increase diabetic patient pool may also augment the growth of the betaxolol market size.

Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1781

According to the reports from a variety of sources, including Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) in 2015, the global prevalence of pulmonary arterial hypertension is projected to be 100,000 – 200,000, that is about 15 - 50 patients per million of the population.

Although treatment available for pulmonary arterial hypertension is limited, beta-adrenergic receptor inhibitor, Prostacyclin and prostacyclin analogs, phosphodiesterase-5 (PDE-5) inhibitors are available to decrease symptoms, slow down disease progression, and improve the quality of life.

Stringent regulatory approvals to ensure the safety of drugs and patent expiry of betaxolol drugs such as Betoptic S and Betoptic Liq, are major challenge for growth of the market, as the generic versions of these drugs are sold at 70% to 80% lower prices as compared to the branded drugs.

Organic and inorganic strategies by market players such as merger, collaboration, acquisition, and research and development for expansion of their business across the regions is expected to boost growth of the market. For instance, in 2016, Humanwell Healthcare Group and PuraCap Pharmaceutical acquired Epic Pharma LLC for $550 million to expand both their commercial and manufacturing capabilities, as well as their presence in the U.S. and international generics market.

Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1781

The market players operating in betaxolol market include Novartis AG, Genix Pharma (Pvt.) Ltd., East West Pharma, Hetero Healthcare Ltd. (GenX), Cadila Pharmaceuticals Ltd., Jawa Pharmaceuticals (INDIA) Pvt. Ltd., DAL Medical Services Company Ltd, Sentiss Pharma Pvt. Ltd., Humanwell Healthcare Group, and PuraCap Pharmaceutical LLC.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.